文献速递糖尿病

老年起病1型糖尿病患者启动CGM与全因死亡率降低相关:VHA目标试验模拟研究

Continuous Glucose Monitoring Initiation Is Associated With Reduced Mortality in Older-Onset Type 1 Diabetes Patients: A Target Trial Emulation Study Within the Veterans Health Administration.
PubMed 文献 · Diabetes Care · 2026-01-01

该研究在退伍军人健康管理局(VHA)成年1型糖尿病患者中开展目标试验模拟(TTE),比较启动持续葡萄糖监测(CGM)者与未启动者的全因死亡率。8,423例初始分配至两种策略,1,039例处方CGM,随访1–4年调整风险比为0.90(95%CI 0.71–0.97)至0.84(95%CI 0.72–0.97),提示CGM启动与全因死亡风险降低相关。

要点

  • 在老年起病1型糖尿病患者中,启动CGM与1–4年全因死亡风险降低相关。
  • 年龄>65岁或未使用胰岛素泵者获益可能更大,但HbA1c、种族或衰弱状态未见效应修饰。
  • 非糖尿病结局(门诊或住院肌肉骨骼或胃肠道疾病)的风险比在组间无差异。

核心结论

  • 在大型目标试验模拟中,启动CGM与老年1型糖尿病患者全因死亡风险降低相关。

研究设计与样本

  • 在退伍军人健康管理局(VHA)观察性健康记录中开展目标试验模拟(TTE)分析。
  • 纳入2017–2020年进行第二次内分泌科就诊的成年1型糖尿病患者,共8,423例初始分配至两种策略。

主要发现

  • 1,039例处方CGM设备,7,399例在6个月宽限期内未被删失或分配CGM。
  • 随访1–4年,调整风险比为0.90(95%CI 0.71–0.97)至0.84(95%CI 0.72–0.97)。
  • 采用3或9个月宽限期时风险比相似。

关键数值与推荐

  • 年龄>65岁或未使用胰岛素泵者获益可能更大,但效应未因HbA1c、种族或民族、衰弱状态而异。
  • 非糖尿病结局(门诊或住院肌肉骨骼或胃肠道疾病)的风险比在组间无差异。

临床怎么用

  • 对于老年起病1型糖尿病患者,可考虑启动CGM以降低全因死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Use of continuous glucose monitoring (CGM) improves glucose control and reduces hypoglycemia, but data are lacking for its possible role in reducing other serious clinical events. RESEARCH DESIGN AND METHODS: We conducted a target trial emulation (TTE) analysis in patients with type 1 diabetes (T1D) comparing all-cause mortality between CGM users and non-CGM users using observational health records from the Veterans Health Administration. Participants included adult T1D patients who had their second endocrine visit (time zero) during years 2017-2020. Each patient was cloned to both treatment strategies but was censored if observed care deviated from the assigned strategy (artificial censoring) during the 6-month grace period. Inverse probability weights accounted for artificial censoring, and negative outcomes examined residual confounding. RESULTS: Of the 8,423 individuals initially assigned to both treatment groups, 1,039 were prescribed CGM devices, while 7,399 were not censored or assigned CGM during the grace period. Mortality was lower with CGM initiation, yielding adjusted risk ratios of 0.90 (95% CI 0.71-0.97) to 0.84 (95% CI 0.72-0.97) over 1-4 years of follow-up. Similar risk ratios were seen with different grace periods (3 or 9 months). Those age >65 years or not on insulin pumps appeared to have greater benefit, but effects did not vary by HbA1c, race or ethnicity, or frailty. Risk ratios did not differ between groups for incident nondiabetes outcomes, including outpatient or inpatient musculoskeletal or gastrointestinal conditions. CONCLUSIONS: In this large TTE of CGM initiation in older T1D patients, CGM use was associated with reduced risk for all-cause mortality.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Reaven PD, Macwan SA, McConeghy K, et al. Continuous Glucose Monitoring Initiation Is Associated With Reduced Mortality in Older-Onset Type 1 Diabetes Patients: A Target Trial Emulation Study Within the Veterans Health Administration. Diabetes Care. 2026. PMID: 42319755. doi:10.2337/dc26-0425

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。